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1. Introduction
Osteoarthritis (OA) is the most common arthritic disorder, affecting increasing numbers of
people in an ageing population [1]. Nearly 27 million people are estimated to have OA among
US adults [2]. OA of the hand is known to cause significant morbidity and can have a severe
impact on patients’ functional capacity. For example, the US Framingham study found that
27% of adults aged over 26 have hand OA (HOA) [2]. In addition, a large European study of
7983 people demonstrated that 25% of participants with hand pain showed significant hand
disability [3]. Hand OA can lead to the development of chronic pain, causing significant
emotional and financial burden to those affected, impacting on carers and on society as a whole
[4]. Treatment of HOA currently comprises analgesia with analgesic drugs including topical
or oral nonsteroidal anti-inflammatory agents (NSAIDs), opioid analgesics and rehabilitative
hand physiotherapy [5]. However, large numbers of people continue to experience impaired
hand function and pain.
Pathologically, OA is typified by cartilage degradation, osteophyte formation and underlying
subchondral sclerosis. More recently, imaging-detected synovitis and bone marrow lesions
have also been found to correlate with OA inflammation and pain. In this chapter we discuss
the recognised clinical phenotypes of hand OA, typical features of hand OA, including
Heberden’s nodes, radiographic correlates of the clinical features observed and new insights
into treatments for this chronic painful arthritic condition.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Clinical phenotypes of hand OA
2.1. Nodal hand OA
Nodal hand OA characteristically involves the distal interphalangeal (DIP) and proximal
interphalangeal (PIP) joints of both hands. A typical swelling of the interphalangeal joints
evolves, which can enlarge to a maximum size during its development (Figure 1). At the early
to mid-stages when enlargement occurs, DIP joints can become painful, erythematous and
difficult to mobilise. The underlying pathogenesis of this process includes bony enlargement
of the underlying interphalangeal joints, synovitis and soft tissue swelling of the region
affected [6]. When involving the DIP joints, the enlargement may give rise to an often typical
feature described as a ‘Heberden’s node’. The historical context of the description of Heber‐
den’s nodes is given further below. The PIP joints are also a recognised feature of nodal hand
OA. They can be associated with a very similar pathological process to the joints described in
DIPs as above and are sometimes called ‘Bouchard’s nodes’ [7]. The radiographic features of
nodal hand OA are demonstrated in Figure 2. Interestingly, the presence of Heberden’s and
Bouchard’s nodes can occur with or sometimes without associated symptoms of pain, stiffness
and disability.
Figure 1. Distal interphalangeal (DIP) joint swelling of the index, middle and ring fingers demonstrating Heberden’s
nodes in a patient with hand OA. The patient also has involvement of the proximal interphalangeal joints (PIP) of the
index, middle and ring fingers (Bouchard’s nodes).
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Figure 2. Radiographic features of nodal hand OA demonstrating DIP joint involvement (index and ring fingers espe‐
cially) with joint space narrowing and osteophyte formation. This patient also has involvement of the first carpometa‐
carpal (CMC) joint of the thumb. The metacarpophalangeal joints are spared, which is often a characteristic finding.
2.2. First carpometacarpal joint OA
The first carpometacarpal (CMC) joint is a distinct recognised feature of hand OA. It is often
seen bilaterally in people affected and is often a major cause of symptomatic joint pain. Risk
factors for first CMC joint hand OA include mechanical factors and manual occupations [8].
The typical radiographic features of CMC joint OA are demonstrated in Figure 2. They often
give rise to a ‘square-shaped’ hand in people affected by this condition. Interestingly nodal
hand OA can co-exist with first CMC joint OA.
2.3. Erosive hand OA
The erosive phenotype of hand OA is a particularly aggressive form of hand involvement. It
is associated with erosions particularly in the DIP and PIP joints [9]. It is important to exclude
other forms of inflammatory arthritis in its management. Typical radiographic features of this
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condition are shown in Figure 3. Historically, clinicians have considered the use of disease-
modifying anti-rheumatic drugs (DMARDs) in this variant to avert the progression of this
erosive form of the disease [10].
Figure 3. Typical radiographic features of erosive hand OA are shown. There has been aggressive erosive damage to
the proximal and distal interphalangeal joints (PIPs) and (DIPs) respectively. A central erosion is observed in several of
these joints with a corresponding characteristic ‘gull-wing’ deformity and osteophytes observed laterally on either
side. The interphalangeal (IP) joint of the thumb is also involved and characteristic joint space narrowing at the first
carpometacarpal (CMC) joint is observed. The metacarpophalangeal joints are characteristically spared.
Other rarer forms of hand OA are also observed in the context of underlying conditions e.g.
inflammatory arthritides, where hand OA can be a secondary phenomenon. The may include
rheumatoid arthritis or the crystal arthropathies including gout and pseudogout. In the crystal
arthropathies, clinical and radiographic appearances can be very similar and may also respond
to similar therapies [11], giving prolonged episodes of joint inflammation and pain. Other
underlying conditions which may give rise to chronic OA of the hands include genetic
conditions such as Stickler’s syndrome, and others such as haemochromatosis, hyperpara‐
thyroidism and acromegaly.
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3. Risk factors for hand OA development
The risk of OA rises with increasing age, with the prevalence of OA increasing over the age of
50 [4]. With respect to the question of whether heavy physical work is associated with hand
OA, some researchers have suggested that heavy occupational work was not associated with
the presence of OA [12] and other studies have favoured a positive correlation of manual work
with OA [13]. Obesity has also been investigated as an independent risk factor for hand OA
with occasionally conflicting results. Hochberg et al. previously suggested that age and not
obesity, were the main risk factor for hand OA [14]. In contrast, Denisov et al. suggested that
obesity was associated with the progression of knee and hand OA in a cohort of almost 300
patients [15]. Cicutinni et al. have also suggested that there is a 9 to 13% increase in knee and
hand OA for every kilogram increase in body weight [16].
Since the range of presentation of hand OA is varied, with several clinical phenotypes
recognised, it is perhaps not surprising that a number of genes have been identified as risk
factors for hand OA. These have been summarised in a recent review [17]. The main themes
which have arisen from genetic studies include the observation that the genetic associations
for hand OA cover a broad nature of genes, perhaps reflecting the multifactorial risk factors
in this condition. Reported genetic associations include a female preponderance carried in
many family cohorts, OA susceptibility loci mapping to chromosome 6 for hip and knee OA.
Recently a group reported a significant association between hand OA and susceptibility loci
on chromosome 6 [18]. In a UK cohort, Zhang et al. have investigated four putatively functional
genetic variants in the KLOTHO gene, which is a strong ageing-related gene [19]. The group
suggested that one variant in the KLOTHO gene was associated with hand OA susceptibility
and especially with osteophyte formation rather than cartilage damage. Further studies have
reported four SNPs in the IL-1R1 gene suggesting an association between the gene encoding
the IL-1R1 and hand OA. Since IL-1 is a cytokine that has catabolic effects on cartilage, this
may be particularly relevant in human disease [20]. Recent work has also focused on the
extracellular matrix protein found in cartilage: aggrecan. Kamareinen et al. [21] showed that
patients homozygous for the most common aggrecan VTNR (variable number of tandem
repeats) allele, A27, had a significantly lower risk of hand OA. People who carried 2 copies of
the aggrecan alleles with less than 27 repeats or more than 27 repeats demonstrated a higher
risk of hand OA. The link between hand OA and extracellular matrix proteins found in cartilage
has received further attention with the recent reports that single nucleotide polymorphisms
(SNPs) in the asporin (ASPN) gene are associated with hand OA progression [22]. A recent
genome-wide association study in an Icelandic population has shown that variants within the
ALDH1A2 gene was associated with hand OA. The variants within the ALDH1A2 gene were
confirmed in replication sets from The Netherlands and UK [23].
Although the studies above suggest a strong familial association with hand OA, the broad
nature of clinical presentation and phenotypes suggests that strong genetic associations with
hand OA are difficult to identify. In future it would be useful to accumulate larger populations
of specific phenotypes to establish genetic associations in greater detail.
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4. Mechanisms of pain in hand osteoarthritis
Osteophytes, which are a pathognomonic feature of OA, are often observed to create a physical
barrier to optimal range of movement and can give rise to severe joint pain as well. Recently,
inflammatory changes have been found to relate to higher risk of structural damage in a study
which looked at 2 years follow-up [6]. Kortekaas and colleagues showed that inflammatory
features, defined by synovial thickening, effusion and increased power Doppler signal on
ultrasound scan (demonstrated in Figure 4), when they persisted, were related to increased
radiographic progression of OA after 2 years. The presence of synovitis by ultrasound may
therefore guide treatment decisions such as corticosteroid-guided intra-articular injection in
hand joints affected by OA.
Figure 4. Ultrasound image of the right first carpometacarpal joint, showing evidence of synovial thickening and in‐
creased vascularity on power Doppler imaging.
Recent work has demonstrated the evidence of bone marrow lesions (BML), which are defined
as high density signal lesions on MRI with T2-weighted imaging, especially in the knee [24],
have also been observed in people with hand OA [25]. In their study, Haugen et al. showed
that bone marrow lesions, synovitis and erosions were associated with joint tenderness. It is
therefore possible that synovitis and bone marrow lesions could be future targets for thera‐
peutic interventions in hand OA.
5. Heberden’s nodes: A historical perspective
"What are those little hard knobs, about the size of a small pea, which are frequently seen upon
the fingers, particularly a little below the top, near the joint? They have no connection with the
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gout, being found in persons who never had it; they continue for life; and being hardly ever
attended with pain, or disposed to become sores, are rather unsightly, than inconvenient,
though they must be some little hindrance to the free use of the fingers." [26]. These were the
observations of William Heberden whose philosophy in medicine was that one must always
be guided by their own direct observations. Heberden’s nodes, which are classical lesions of
osteoarthritis, were initially described as ‘digitorum nodi’ in Latin by Heberden himself, which
led him to make the important distinction between gout and osteoarthritis [27]. OA remains a
common disabling condition worldwide and the most common form of arthritis [28]. However,
there are few diagnostic tests and unfortunately current treatments for OA have not been able
to successfully eliminate pain from the clinical manifestations of the disease [5].
In addition to Heberden’s description further observation of the nodes have led them to be
classified according to the location (Figure 1). Nodes either appear on the lateral aspect on the
dorsolateral margins or in the central midline where occasionally they fuse with the lateral
nodes to form a ridge. They can also be classified as idiopathic or traumatic, with the latter
most commonly resulting in a solitary Heberden node [29]. Idiopathic nodes are easily
identifiable from the clinical history, which usually consists of a node, which slowly and
gradually increases in size on one finger and then spreads to other fingers. Reports from
patients about pain associated with the nodes are inconsistent, with some reporting painful
growth of the nodes whereas others report the growth as painless [30]. Stecher [29] described
the progression of Heberden’s nodes having observed around 7,000 individuals with Heber‐
den’s nodes. He noted that the progression could be divided into three stages. The initial stage
consists of a visible enlargement of the joint; this enlargement is also palpable at the proximal
end of the distal phalanx as two spherical nodules or as prominent ridge. In some people it
was noted that the enlargement was so severe that the nodules were palpable at the sides of
the joint and on the palmar surface. The second stage consists of palmar flexion of the distal
phalanx in addition to the enlargement. In addition to the previous two stages the third stage
consists of lateral deviation of the distal phalanx from the midline (see Figure 1) [29].
It is well established that Heberden’s nodes are associated with underlying radiographic
changes [30]. More recent studies have shown that Heberden’s nodes, which are more
developed and affecting both sides of the joint show joint space narrowing as opposed to
Heberden’s nodes in their initial stages. This can be attributed to the slow growth of Heberden’s
nodes and that joint space narrowing is possibly a late manifestation of the disease [31]. With
this knowledge it can be assumed that Heberden’s nodes affecting both aspects of the joint can
be used as a clinical marker for radiographic change [31].
OA is a process of cartilage and bone damage in which changes are eventually irreversible.
However it seems that Heberden’s nodes have a different process governing their formation
and they are histologically different depending on the location on the joint. Midline nodes are
traction spurs growing in the extensor tendon, this growth is usually found in athletes as a
physiological response to excessive tension. It is important to note that this spur is not a true
osteophyte and that it can be identified by its location and the lack of a cartilage cap. Con‐
versely, the lateral node has shown to have a constant presence of osteophyte, which arises
from one or both of the phalanges and is located lateral to the extensor tendon. These histo‐
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logical findings are supported by radiological observation. Radiography of Heberden’s nodes
shows that there is evidence of osteophyte formation in the lateral node and a traction spur in
the middle node [31]. Osteophytes consist of both new bone and cartilage formation, which
arise from progenitor cells, indicating that the sequelae of joint destruction induces a pluri‐
potent cell response [32]. The exact function of osteophytes in osteoarthritis is yet be under‐
stood but can been seen as an adaptive mechanism against joint injury to stabilize the joint [33,
34]. Analysis of osteophytes at different developmental stages has shown a sequential process
of differentiation and the presence of the anabolic factor transforming growth factor-beta (TGF-
β) [32]. Osteophyte growth usually occurs in the direction of least resistance; in joints such as
the shoulder and ankle the strong capsules restrict osteophyte growth. At the distal interpha‐
langeal joint the only obstruction is a thin capsule, which holds in synovial fluid. This ob‐
struction is not sufficient to restrict osteophyte growth hence the presence of such prominent
Heberden’s nodes. To what extent the osteophyte causes deviation of the distal phalanx is
dependent on the strength of the collateral ligament, which is genetically determined [31].
Extensive research by Stecher has shown that there may be a single autosomal gene responsible
for the inheritance of Heberden’s nodes however it seems to exhibit a sex-linked pattern as it
is dominant in females and recessive in males [29].
Although Heberden’s nodes were first described over 150 years ago and despite extensive
research their exact mechanism and purpose has not been fully understood. They are part of
the clinical picture of osteoarthritis but it seems that their pathophysiology and genetic
inheritance somewhat differs to our current understanding of generalised osteoarthritis.
6. Treatments for hand osteoarthritis
A range of treatments have been used in hand OA, including physical techniques such as
taping and splinting to reduce pain and improve function [35, 36]. Such treatment is often
administered through physiotherapy and/or occupational therapy units and can be repeated
during flares.
Pharmacological  treatments  are  often focused around symptomatic  pain  relief  including
paracetamol,  topical  and  oral  non-steroidal  anti-inflammatory  drugs  such  as  ibuprofen,
naproxen  and  others,  which  have  been  shown  to  be  efficacious  over  and  above  other
analgesic treatments in large scale meta-analyses [4]. Such treatments are now recommend‐
ed within several  international  guidelines  for  the treatment  of  OA [36].  Recent  imaging
studies  which have shown synovitis  and bone marrow lesions to  correlate  with painful
progressive hand OA have led to renewed interest in considering disease-modifying anti-
rheumatic agents for hand OA.
Previous studies have shown that intra-articular injections of corticosteroid can be particularly
beneficial in hand OA, particularly at the first CM joint [37]. However, repeated injections are
not without significant side-effects, including local tissue damage and skin atrophy. The
general consensus is that, if not straightforward, local injections may best be performed under
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ultrasound guidance. Some reports have suggested intra-articular hyaluronic acid may also
be a potential therapeutic option, but such studies have not yet been subjected to large scale
clinical trials [38]. With respect to systemic steroid, a recent study showed improvement in
synovitis following intramuscular depomedrone injection of steroid for hand OA, which was
sustained for 4 weeks [39]. However, the effects of systemic corticosteroid treatment were
relatively short-lived and synovitis returned by ultrasound measures after 12 weeks of
treatment.
With respect to the use of other disease-modifying agents, a recent trial of hydroxychloroquine
has been conducted for the treatment of hand OA [40] and the results of this study are now
awaited. Other groups have investigated the use of bisphosphonates e.g. intravenous clodro‐
nate in the treatment of hand OA with beneficial outcome for pain in their study [41]. However,
a recent meta-analysis by our group did not show overall significant benefit overall for pain
and function after use of bisphosphonates across several phenotype of OA, including hip, knee
and hand [42]. Future studies targeted at specific stages of disease with proven synovitis and
bone marrow lesions may be more helpful in establishing the potential future therapeutic use
of bone-modulating agents in the clinic.
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